



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

**PRELIMINARY PRIORITY LIST OF HTA 2022 UNDER THE GENERAL TRACK
FOR PUBLIC CONSULTATION FROM 12 TO 26 SEPTEMBER 2022**

As a follow through on the Health Technology Assessment Council (HTAC) and the Health Technology Assessment Division (HTAD)'s call for HTA topic nominations last 04 April to 27 May 2022, and as issued through Department Circular No. 2022-0183 dated 21 March 2022 with the subject "*Opening of the 2022 Call for Topic Nomination*", HTA Philippines is pleased to report that out of 140 nominations submitted, the HTAD has received a total of 88 complete submissions from various stakeholder groups (i.e., industries, patient groups, societies, government) consisting of 86 nominations for new health technologies and 2 nominations for existing health technologies. New health technologies are those that are not yet covered by DOH or PhilHealth while existing health technologies refer to those which are currently covered by DOH or PhilHealth to proceed to HTA for rationalization or optimization. These complete submissions were eventually subjected to review for prioritization using the *HTA Prioritization Criteria* as stipulated in the *Annex F* of the HTA Process Guide: <https://hta.doh.gov.ph/philippine-hta-process-guide/>

HTA Philippines hereby makes public its preliminary list of priority topics for HTA 2022 (*Annex A*) with 25 assessments composed of 33 health technology topics. Please refer to *Annex B* and *Annex C* for more information. All comments, inputs, and/or appeals may be submitted until **26 September 2022**, for the consideration of the HTAC, through email at hta@doh.gov.ph.

Please use the prescribed form for appeals for the topic prioritization which is accessible through this link: hta.doh.gov.ph/topic-nomination/. You may also submit hard copies of your appeals at the 4th floor, Philippine Blood Disease, and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon City. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

The HTAD will also be conducting a Virtual Public Consultation on **19 September 2022** (Monday) from 2:00 PM to 4:00 PM for easier facilitation and addressing of concerns. If you are interested to join, kindly email the HTAD for more details.

Please note that inclusion to the HTA 2022 priority list does not guarantee that the topics will receive positive recommendations from the HTAC, as prioritized topics will still undergo assessments, which will take place only after the appeals period. Once prioritized, the HTAD shall keep the HTA website updated on the status of topic assessments through this link: <https://hta.doh.gov.ph/status-of-health-technologies-assessments/>.

Should you have further questions or concerns, you may coordinate with HTAD through email at hta@doh.gov.ph or at telephone numbers (02) 875-7734 local 253 or 8937-5314. Thank you very much and best regards.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Director IV

Health Technology Assessment Division

Health Regulation Team

Preliminary list of prioritized topics for NEW HEALTH TECHNOLOGIES

No.	Type of Health Technology	Health Technology	Dosage form and strength	Applied Indication	Proponent
1	Drug	Atezolizumab	60 mg/mL, 20 mL vial for intravenous (IV) infusion	Unresectable hepatocellular carcinoma (HCC)	Roche (Philippines)
		Lenvatinib	4mg capsule		Hi-Eisai Pharmaceuticals
2	Drug	Atezolizumab	60 mg/mL, 20 mL vial for IV infusion	Metastatic non-small cell lung carcinoma (NSCLC)	Roche (Philippines)
		Pembrolizumab	100mg/4mL (25mg/mL) solution for injection (IV infusion)		Philippine Society of Medical Oncology Merck Sharp & Dohme (I.A.) LLC
3	Drug	Biphasic Insulin Aspart 30	100 units/mL suspension for injection in pre-filled pen	Type 2 diabetes mellitus in adults	Novo Nordisk Philippines Inc.
4	Drug	Brexpiprazole	250mcg, 500mcg, 1mg, 2mg, 3mg, 4mg tablets	Major depressive disorder	PhilHealth
		Paroxetine	20mg film coated tablet		DOH-Disease Prevention and Control Bureau

					(DOH-DPCB)
		Vortioxetine	5mg, 10mg, 15mg, 20mg tablets		PhilHealth
5	Drug	Ceftaroline fosamil	600 mg powder for concentrate for solution for injection	Community-acquired pneumonia (CAP)	Pfizer Philippines
6	Drug	Ceftazidime/Avibactam	2g/500mg powder for concentrate solution	Hospital-acquired Pneumonia (HAP), including ventilator associated pneumonia (VAP) Infections	Pfizer Philippines
		Ceftolozane/Tazobactam	1g/500 mg IV powder for injection		San Lazaro Hospital
7	Drug	Cilostazol	100 mg sustained release capsule	Treatment of ischemic symptoms; prevention of recurrence of cerebral infarction (excluding cardiogenic cerebral embolism)	Stroke Society of the Philippines
8	Clinical Equipment and Devices (CED)	Colonoscopy	N/A	Diagnosis colorectal cancer as confirmatory test or procedure if found positive on fecal occult blood test	DOH-DPCB
9	Drug	Erdosteine	300 mg capsule	Treatment of chronic obstructive pulmonary disease (COPD)	OEP Philippines
10	Medical and	High-Risk Human Papilloma Virus (HPV)	N/A	Early detection of cervical cancer	DOH-DPCB

	Surgical Procedure (MSP)	Testing (DNA Test)			
11	Drug	Insulin degludec	100 units/mL pre-filled pen	Type 2 diabetes mellitus in adults	Novo Nordisk Philippines Inc.
12	Vaccine	Japanese encephalitis vaccine	Single dose of 0.5mL containing 5.4 lg PFU of live attenuated JE Virus	<div>Active immunization against Japanese Encephalitis Virus (JEV) and its complications encephalitis among children aged 1 year and above.</div> <div>Active immunization against Japanese Encephalitis Virus (JEV) and its complication clinical meningitis among children aged 1 year and above.</div>	DOH-DPCB
13	Drug	Labetalol Hydrochloride	5mg/mL (100mg/20 mL) solution for injection	Management of hypertensive disorders in pregnancy	Manila East Medical Center
14	Drug	Liraglutide	6mg/ml solution for injection in pre-filled pen	Type 2 diabetes mellitus in adults	Novo Nordisk Philippines Inc.
15	CED	Mammography	N/A	Screening of breast cancer	DOH-DPCB
16	CED	Newborn Pulse Oximetry	N/A	Indirectly detecting hypoxemia in medically ill patients that may	DOH-DPCB

				raise suspicion for a critical congenital heart disease (CCHD)	
17	Drug	Palbociclib	75 mg, 100 mg, 125 mg capsule	Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer	Pfizer Philippines Philippine Society of Medical Oncology
		Ribociclib	200mg film-coated tablet		Philippine Society of Medical Oncology
18	Drug	Paroxetine	20mg film-coated tablet	Post-traumatic stress disorder	DOH-DPCB
19	Vaccine	Pneumococcal Conjugate Vaccine -13 [PCV 13-Valent] (Adsorbed)	0.5 mL suspension for IM injection	All adults including senior citizens and patients with comorbidities/risk factors (Invasive pneumococcal disease)	Pfizer Philippines
				All adults including senior citizens and patients with comorbidities/risk factors (Pneumonia)	
20	Drug	Reteplase	10 Units Lyophilized Powder for Injection IV	Acute myocardial infarction	PhilHealth
21	Vaccine	Rotavirus vaccine	1.5mL, Oral Suspension	Prevention of rotavirus, the most common cause of severe gastroenteritis among children less than 1 year of	DOH-DPCB
			2.5mL, Freeze-dried Powder		

			for Oral Suspension	age"	
22	Drug	Trastuzumab emtansine	100 mg or 160 mg powder for concentrate for solution for IV infusion	Adjuvant treatment of people with HER2+ eBC with residual invasive disease after neoadjuvant treatment	Roche (Philippines)
23	MSP	Ultrasound with Alpha-Fetoprotein (AFP)	N/A	Screening of patients at risk to develop hepatocellular carcinoma who have or have not progressed to cirrhosis	DOH-DPCB

Preliminary list of prioritized topics for EXISTING HEALTH TECHNOLOGIES					
No.	Type of Health Technology	Health Technology	Dosage form and strength	Applied Indication	Proponent
1	MSP	Renal replacement therapy	N/A	Chronic kidney disease	PhilHealth
2	Vaccine	Shift from two-dose to one-dose Human Papillomavirus (HPV) Vaccine	0.5 mL suspension	Prevention of cervical cancer	DOH-DPCB

ANNEX B. NOMINATIONS RECEIVED BY THE HTA DIVISION

Status	# Nominations (N)	Percentage (N/Total nominations received)
Eligible applications for prioritization (NEW HEALTH TECHNOLOGY TOPICS)	87	61.7%
Eligible applications for prioritization (EXISTING HEALTH TECHNOLOGY TOPICS)	2	1.4%
Rejected applications due to non-compliance with requirements and other related concerns	50	35.5%
Withdrawn applications	2	1.4%
Total nominations received	141	N/A

ANNEX C. TALLY OF THE FINAL 31 NEW HEALTH TECHNOLOGY ASSESSMENT TOPICS

TALLY OF FINAL 31 NEW HEALTH TECHNOLOGIES							
BY TYPE OF HT		BY PROPONENT		BY INDICATION			
Drug	21/59	DOH Program	11/23	Auto-immune	0/2		
Vaccine	5/7	Professional Society	2/7	Blood disorder	0/2		
MSP	2/4	PhilHealth	3/4	Cancer	11/15		
CED	3/3	Industry	13/43	Cardiovascular	4/7		
PPH	0/1	Hospital	2/7	Dermatologic	0/4		
Other HT	0/0	Patient Group	0/4	Diabetes	3/10		
TradMed	0/2	<p>Note: There will be inconsistencies with the tally of the number of topic nominations from the proponents in Annex B as the table above accounts for the number of topics. Meanwhile, the ‘By Proponent’ section in Annex C accounts for topics with multiple proponents and vice versa.</p>		GI tract disease	0/3		
				Infectious disease	6/11		
				Mental Health	4/10		
				Pain	0/4		
				Pulmonary	1/2		
				Sedation	0/1		
				Vector-borne	2/4		